RDY News & Events

Dr. Reddy's Laboratories announced that it has received a Notice of Compliance, NOC, from Health Canada for its generic Semaglutide Injection. Dr. Reddy's becomes the first company to receive the market authorization for generic Semaglutide Injection in Canada, ahead of Health Canada's review target date. The market authorization covers the 2 mg / pen and 4 mg / pen. With launch preparations underway, Dr. Reddy's is well-positioned to bring this important treatment option available to Canadian patients.

Dr. Reddy's Laboratories is still awaiting approval for Semaglutide in Canada, sources with knowledge of the matter told CNBC-TV18's Ekta Batra. Analysts who track Dr. Reddy's expect six to nine months of no competition in the Canadian market, the report noted. Semaglutide is a GLP-1 receptor agonist primarily used for treating Type 2 diabetes and chronic weight management that is sold under brand names Ozempic, Wegovy, and Rybelsus.